Obviousness

Based on my analysis of U.S. Patent No. 11,938,201 and the state of the art preceding its priority date of October 23, 2017, a strong case for obviousness under 35 U.S.C. § 103 can be made by combining prior art references that teach the key components of the claimed invention.

Analysis of Obviousness

The core of the invention as described in claim 1 of US patent 11,938,201 is a compound with the general structure B-L-A:

• A: A targeting moiety for Fibroblast-Activation Protein-alpha (FAP-α), specifically a quinoline-based structure.
• L: A linker moiety.
• B: An imaging or radiotherapeutic moiety (e.g., a chelator for a radioisotope or an optical dye).

An invention is considered obvious if the differences between it and the prior art are such that the subject matter as a whole would have been obvious to a Person Having Ordinary Skill in the Art (PHOSITA) at the time of the invention. For this technology, a PHOSITA would be a medicinal or radiopharmaceutical chemist with experience in designing targeted molecular agents for imaging and therapy.

A compelling obviousness argument can be constructed by combining a primary reference disclosing the FAP-α targeting moiety (A) with a secondary reference teaching the well-known methodology of converting small-molecule inhibitors into imaging agents via linkers and chelators (the B-L platform).

---

Prior Art Combination and Motivation

1. Primary Reference: Prior Art Disclosing the FAP-α Targeting Moiety (A)

The patent’s detailed description cites several publications describing FAP-α inhibitors that predate the 2017 priority date. For example, a series of papers by Jansen et al. (e.g., J. Med. Chem. 2013, 56, 19, 7612–7624 and J. Med. Chem. 2014, 57, 11, 4570–4584) discloses potent and selective, low-molecular-weight (LMW) inhibitors of FAP-α. These publications describe compounds with the same core quinoline-based chemical structure that serves as the targeting moiety A in the '201 patent.

• What this reference teaches: A PHOSITA would learn from Jansen et al. of a specific class of LMW compounds that bind effectively and selectively to FAP-α. This provides the essential FAP-α targeting "warhead" of the invention.

2. Secondary Reference: Prior Art Disclosing the B-L-Inhibitor Platform

The '201 patent itself incorporates by reference U.S. Patent Application Publication Nos. US2011/0064657 A1 and US2012/0009121 A1 (Pomper et al.). These references are cited explicitly in the '201 patent for their disclosure of "Suitable linkers" (Column 15, lines 34-45). These Pomper references teach the design and synthesis of LMW imaging agents targeting Prostate-Specific Membrane Antigen (PSMA). Crucially, they describe the now-standard methodology of taking a known LMW enzyme inhibitor and conjugating it to an imaging or therapeutic moiety (B) via a versatile linker (L). They disclose various linkers and chelators (such as DOTA) for attaching radioisotopes, which are the same types of linkers and chelators used in the '201 patent.

• What this reference teaches: A PHOSITA would learn from Pomper et al. a proven, successful, and modular strategy for converting any given LMW enzyme inhibitor into a highly effective imaging or radiotherapeutic agent. This provides the B-L- platform and the chemical methods for attaching it to a targeting molecule.

3. Motivation to Combine the References

A PHOSITA in 2017 would have been clearly motivated to combine the teachings of Jansen et al. and Pomper et al. for the following reasons:

• Recognized Problem: The background section of the '201 patent clearly identifies FAP-α as an excellent, "potential imaging and radiotherapeutic target" for a vast majority of cancers. It also explicitly states the key problem with existing FAP-α targeting agents: antibody-based approaches suffer from "slow blood and non-target tissue clearance," making them suboptimal for imaging.
• Known Solution: The patent background further states that "Low molecular weight (LMW) agents demonstrate faster pharmacokinetics and a higher specific signal." This establishes a clear goal in the field: develop an LMW FAP-α imaging agent to solve the known pharmacokinetic problems of antibodies.
• Obvious Path Forward: Faced with this goal, a PHOSITA would naturally look for a known, potent LMW FAP-α inhibitor. The work by Jansen et al. provides a perfect candidate. The next logical step would be to figure out how to label this inhibitor for imaging. The highly successful and analogous work in the PSMA field, detailed in the Pomper et al. references, provides an established and validated blueprint for doing exactly that. The motivation is not one of speculation but of applying a standard, successful technique from one area of targeted radiopharmaceuticals (PSMA) to another (FAP-α) to solve a well-defined problem.
• Reasonable Expectation of Success: The structural similarity of the targets (both are cell-surface proteases) and the immense success of the LMW PSMA-targeted agents would provide a PHOSITA with a high degree of confidence that attaching a chelator to a Jansen-type FAP-α inhibitor via a suitable linker would yield a successful FAP-α imaging agent. The core principle—linking a small molecule inhibitor to an imaging reporter—is directly transferable, leading to a reasonable expectation of success.

In summary, the combination of a reference like Jansen et al. (teaching the FAP-α targeting scaffold A) and a reference like US2011/0064657 (teaching the B-L platform for converting inhibitors into imaging agents) would have rendered the invention claimed in US patent 11,938,201 obvious to a person of ordinary skill in the art at the time of invention.